|
Apr 1
|
INmune Bio, Inc. (NASDAQ:INMB) Q4 2023 Earnings Call Transcript
|
|
Mar 31
|
INmune Bio Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
|
|
Mar 29
|
INmune Bio Inc (INMB) Posts Year-End Earnings, Reveals Net Loss Amidst Clinical Advancements
|
|
Mar 28
|
INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update
|
|
Mar 26
|
INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28
|
|
Mar 13
|
INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy
|
|
Mar 5
|
INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™
|
|
Feb 6
|
INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024
|
|
Feb 4
|
Insiders own 24% of INmune Bio, Inc. (NASDAQ:INMB) shares but retail investors control 53% of the company
|
|
Jan 2
|
INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer
|
|
Dec 18
|
INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDA
|
|
Nov 29
|
INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium
|
|
Nov 27
|
INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease
|
|
Sep 7
|
INmune Bio Inc. to Present at Baird Global Healthcare Conference and H.C Wainwright 25th Annual Global Investment Conference
|
|
Sep 5
|
INmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer’s Disease
|
|
Aug 8
|
INmune Bio, Inc. (NASDAQ:INMB) Q2 2023 Earnings Call Transcript
|
|
Aug 8
|
Q2 2023 INmune Bio Inc Earnings Call
|
|
Aug 7
|
INmune Bio Inc. Announces Second Quarter 2023 Results and Provides Business Update
|
|
May 24
|
INmune Bio Inc.’s Chief Scientific Officer, Mark Lowdell, Ph.D. to Present Plenary Talk at International Society of Cell & Gene Therapy
|